Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acetyldigoxin is a cardiac glycoside and an acetyl derivative of digoxin, primarily used to treat acute and chronic heart failure as well as certain arrhythmias such as atrial fibrillation. It exerts its effects by increasing the force of myocardial contraction (positive inotropy) while reducing heart rate and conduction velocity through the atrioventricular node. The mechanism of action involves inhibition of the sodium/potassium-transporting ATPase subunit alpha-1 (Na+/K+ ATPase) in cardiac myocytes, leading to increased intracellular sodium and subsequent elevation of intracellular calcium via reduced activity of the sodium-calcium exchanger. This results in enhanced contractility without a significant increase in energy expenditure by the heart. Acetyldigoxin is better absorbed and has a longer duration of action than digoxin[1][2][3][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acetyldigoxin.